Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,926,352
  • Shares Outstanding, K 2,508,090
  • Annual Sales, $ 40,921 M
  • Annual Income, $ 4,285 M
  • 36-Month Beta 0.82
  • Price/Sales 2.72
  • Price/Cash Flow 8.99
  • Price/Book 1.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.98
  • Number of Estimates 3
  • High Estimate 1.02
  • Low Estimate 0.95
  • Prior Year 1.00
  • Growth Rate Est. (year over year) -2.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.41 +4.53%
on 10/12/18
45.23 -1.99%
on 10/01/18
+0.52 (+1.19%)
since 09/14/18
3-Month
40.26 +10.11%
on 08/15/18
45.23 -1.99%
on 10/01/18
+2.58 (+6.18%)
since 07/16/18
52-Week
37.43 +18.43%
on 05/09/18
50.04 -11.41%
on 10/19/17
-5.30 (-10.68%)
since 10/16/17

Most Recent Stories

More News
Emergent Completes Acquisition of Narcan Maker Adapt Pharma

Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.

GNMSF : 139.0000 (-0.57%)
EBS : 63.32 (+4.77%)
GSK : 39.80 (+2.37%)
SNY : 44.33 (+2.07%)
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary...

SAN : 4.97 (+1.02%)
REGN : 398.52 (+5.55%)
SNY : 44.33 (+2.07%)
3 Large-Cap Pharma Stocks Performing Better Than Industry

We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

AZN : 39.09 (+4.32%)
MRK : 71.22 (+2.53%)
LLY : 111.03 (+0.37%)
NVS : 85.77 (+3.15%)
SNY : 44.33 (+2.07%)
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

CRSP : 39.56 (+10.19%)
AZN : 39.09 (+4.32%)
SNY : 44.33 (+2.07%)
MACK : 5.09 (+0.99%)
Keeping Women In STEM Careers: Looking to Data For Answers

Companies across industries from IT to biopharma have long emphasized the importance of recruiting and maintaining women in jobs in the so-called STEM fields - Science, Technology, Engineering, and Math....

SNY : 44.33 (+2.07%)
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

EBS : 63.32 (+4.77%)
INO : 5.58 (+4.49%)
VXRT : 3.21 (-13.71%)
SNY : 44.33 (+2.07%)
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs

The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.

GILD : 76.30 (+4.84%)
GERN : 1.83 (+10.24%)
REGN : 398.52 (+5.55%)
AMGN : 202.34 (+3.45%)
SNY : 44.33 (+2.07%)
ALXN : 127.72 (+5.13%)
Here's Why Alynlam Pharmaceuticals is Hogging the Limelight

Alnylam (ALNY) files an NDA for Onpattro in Japan and releases positive interim results for givosiran.

MDCO : 28.08 (+4.27%)
ALNY : 82.91 (+3.62%)
NVS : 85.77 (+3.15%)
SNY : 44.33 (+2.07%)
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer

Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.

AZN : 39.09 (+4.32%)
MRK : 71.22 (+2.53%)
REGN : 398.52 (+5.55%)
SNY : 44.33 (+2.07%)
Sanofi aims to topple the flu as it marks National Seniors Day with a Guinness World Record attempt

Today, Sanofi Pasteur, the vaccine division of Sanofi, marks National Seniors Day with an attempt to set a world record using tissue box dominoes to show that for seniors, seasonal influenza needs more...

SNY : 44.33 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 43.87
1st Resistance Point 43.65
Last Price 44.33
1st Support Level 43.27
2nd Support Level 43.11

See More

52-Week High 50.04
Fibonacci 61.8% 45.22
Last Price 44.33
Fibonacci 50% 43.74
Fibonacci 38.2% 42.25
52-Week Low 37.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar